|
Disseminated on behalf of Helus Pharma 
(NASDAQ: HELP) |
| | The Experts Failed. The Market Broke. The Opportunity is Here. |
|
|
When a system fails this badly, it's a sign for investors to pay attention. |
Dear Reader, |
I'm not a stock picker. I'm a teacher. |
My goal is to teach you to see the world as it is, not as the so-called "experts" tell you it is. And right now, the experts are presiding over a broken system. |
Look at the market for anxiety treatments. It's a case study in failure. |
More than 20 million Americans suffer from Generalized Anxiety Disorder. For half of them, the standard drugs, the ones pushed by Big Pharma for decades, don't work well enough. |
Yet for nearly two decades, the FDA has not approved a single new type of monotherapy. And in its entire history, it has never approved an "add-on" treatment for those who are still suffering. |
This is not a scientific failure. This is a system failure. |
It's the result of a bloated bureaucracy and a pharmaceutical industry that got lazy and risk-averse. They chose the easy path of milking old patents, and millions of people were left behind in a state of constant worry and fear. |
When a system breaks this completely, it creates a vacuum. And into that vacuum, an opportunity emerges for those who are paying attention. |
The system failed. See the opportunity it created. |
That's why the recent news from Helus Pharma (NASDAQ: HELP) is so important. |
On March 5th, the company released data from a study of its new anxiety treatment, HLP004. |
This wasn't just another "me-too" pill. It's a novel compound designed to work differently than the old drugs that have failed so many. It represents a new approach, a new asset in a field starved of real innovation. |
The results were a clear signal. |
Patients, who were already on standard drugs, saw their anxiety scores drop by a mean of 10.4 points. This was an improvement above and beyond what the old drugs could do. |
Think about what that means. For people who thought they were out of options, this was a lifeline. It was a sign that a real solution might be possible. |
By the six-month mark, 67% of patients had a significant response, and nearly 40% were in remission. The treatment was also well-tolerated, a critical factor for both patients and potential acquirers. |
This is what a breakthrough looks like. It's a real solution in a market that the establishment gave up on. |
And here's what makes it even more compelling. The treatment is fast. Patients were ready to leave the clinic in about three hours. That means this isn't some complicated, multi-day procedure. It fits into the existing infrastructure of psychiatric clinics across the country. It's commercially scalable from day one. |
For an investor, this is a powerful lesson. The greatest opportunities are often found in the wreckage of a broken system. You don't find them by following the herd. You find them by looking for the innovators who are quietly building real assets. |
Helus Pharma has created a valuable asset, a potential first-in-class drug for a massive, underserved market. They did it by ignoring the broken system and focusing on the real need. |
Now, the system will be forced to pay attention. |
Remember, Helus Pharma isn't just an anxiety story. Their lead drug, HLP003, is in Phase 3 trials for major depressive disorder and has already received Breakthrough Therapy Designation from the FDA. That's a dual-threat pipeline in two of the largest unmet needs in medicine. |
The analysts at Jefferies are already projecting a potential 100% to 200% stock move on the company's upcoming Phase 3 data readout. |
I don't know what the stock will do. But I know an asset when I see one. |
Your job is to get educated. |
See the data the establishment ignored |
To your financial freedom, |
Money Power and Profit |
P.S. The government and Big Pharma failed to solve the anxiety crisis. A small outsider may have just done it for them. That's how real wealth is created: by solving problems the system can't. Educate yourself on what they've built. |
|
IMPORTANT DISCLAIMER & DISCLOSURES |
Investing in early-stage technology stocks is HIGH RISK, and past performance does not guarantee future results. Please conduct independent research before making any investment decisions. You could lose all of your investment. |
Freedom Financial Research LLC., as a publisher, is not a broker, investment advisor, or financial advisor in any jurisdiction. |
Please do not rely on the information presented by Freedom Financial Research as personal investment advice. |
If you need personal investment advice, kindly reach out to a qualified and registered broker, investment advisor, or financial advisor. |
The communications from Freedom Financial Research should not form the basis of your investment decisions. Examples we provide regarding share price increases related to specific companies are based on randomly selected time periods and should not be taken as an indicator or predictor of future stock prices for those companies. |
Helus Pharma is a paid sponsor of this report. |
The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom. |
Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter. Freedom Financial Research nor any employee of Freedom Financial Research is not registered with the United States Securities and Exchange Commission (the "SEC"): as a "broker-dealer" under the Exchange Act, as an "investment adviser" under the Investment Advisers Act of 1940, or in any other capacity. |
Freedom Financial Research, its owners, directors, and employees are also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity. |
HIGHLY BIASED: In our role, we aim to highlight specific companies for your further investigation; however, these are not stock recommendations, nor do they constitute an offer or sale of the referenced securities. Freedom Financial Research has received cash compensation in the amount of USD $125,000 by a third party, CDMG Inc. for a one-month Helus Pharma profile beginning March 19, 2026 and is thus extremely biased. It is crucial that you conduct your own research prior to investing. This includes reading the companies' SEC filings, press releases, and risk disclosures. The information contained herein regarding Helus Pharma has been derived from its and SEC filings, including scientific and technical information. Information regarding the projects underlying Helus Pharma's interests has been derived from the publicly available disclosure of the underlying operators and owners, including where referenced herein. |
Freedom Financial Research, and its directors, employees, and members of their households do not own any shares of Helus Pharma (NASDAQ: HELP). |
However, Freedom Financial Research is extremely biased since this is a sponsored editorial. |
HIGH RISK: The securities issued by the companies we feature should be seen as high risk; if you choose to invest, despite these warnings, you may lose your entire investment. You must be aware of the risks and be willing to accept them in order to invest in financial instruments, including stocks, options, and futures. |
NOT PROFESSIONAL ADVICE: By reading this, you agree to all of the following: You understand this to be an expression of opinions and NOT professional advice. You are solely responsible for the use of any content and hold Freedom Financial Research, and all partners, members, and affiliates harmless in any event or claim. While Freedom Financial Research strives to provide accurate and reliable information sourced from believed-to-be trustworthy sources, we cannot guarantee the accuracy or reliability of the information. The information provided reflects conditions as they are at the moment of writing and not at any future date. Freedom Financial Research is not obligated to update, correct, or revise the information post-publication. |
FORWARD-LOOKING STATEMENTS: Certain information presented may contain or be considered forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in these statements. There can be no assurance that any such statements will prove to be accurate, and readers should not place undue reliance on such information. These statements are subject to known and unknown risks including those set forth in Helus Pharma's most recent annual information form and other public filings available at www.sedarplus.ca and www.sec.gov. Neither Freedom Financial Research nor Helus Pharma undertake any obligations to update the information presented or to ensure that such information remains current and accurate, except as required under applicable law. |
Tidak ada komentar:
Posting Komentar